TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: ADAR1 edits the 3ʹUTR of MDM2 to prevent targeting by miR-155, leading to increase MDM2 levels and inhibit the activation of p53, thereby promoting the progression of CML